Mitazalimab (ATOR-1017)

About Alligator Bioscience AB

Alligator Bioscience is a clinical-stage biotech focused on developing tumor-directed antibody therapies for cancer. Its core strategy is built on proprietary platforms like ALiCE® and RUBY™ to generate highly specific, next-generation immuno-oncology drugs. The company's most advanced program, mitazalimab (a CD40 agonist), is in a pivotal Phase 2/3 trial for metastatic pancreatic ductal adenocarcinoma (PDAC), representing a significant near-term value inflection point. Alligator operates as an R&D-centric organization, advancing its pipeline through internal development and strategic partnerships.

Therapeutic Areas